Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAlimera Sciences Inc

Alimera Sciences Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2024-10-09T19:00:43.705845Z
Market Cap
163.45M

Momentum Score

…

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
2.46
Low
4.38
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
5.54
Dividend Yield
-
Revenue TTM
80.75M
Revenue Per Share
3.16
Gross Profit TTM
52.00M
Debt / Equity
1.46
ROE
-158.76%
Net Debt
55.31M
ROCE
-8.84%
Diluted EPS TTM
-0.25

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -18.08M -3.93M -5.41M -10.23M -16.28M
Net income -18.11M -4.37M -5.34M -10.44M -16.38M
Selling general administrative 12.87M 12.77M 11.65M 13.95M 14.53M
Selling and marketing expenses 25.99M 23.07M 20.38M 25.00M 23.52M
Gross profit 46.15M 52.00M 43.88M 47.32M 42.29M
Reconciled depreciation 2.71M 2.58M 2.68M 2.64M 2.65M
Ebit -11.64M -0.20M -0.50M -5.27M -9.67M
Ebitda -8.93M 2.38M 2.17M -2.63M -7.03M
Depreciation and amortization 2.71M 2.58M 2.68M 2.64M 2.65M
Non operating income net other - - 0.47M -0.08M -1.83M
Operating income -11.64M -0.20M -0.50M -5.27M -9.67M
Other operating expenses 65.77M 59.23M 51.32M 59.22M 56.64M
Interest expense 5.88M 5.41M 5.38M 4.87M 4.78M
Tax provision 0.03M 0.44M -0.07M 0.22M 0.11M
Interest income - - - 4.95M 4.84M
Net interest income -5.88M -5.41M -5.38M -4.87M -4.78M
Income tax expense 0.03M 0.44M -0.07M 0.22M 0.11M
Total revenue 54.13M 59.03M 50.82M 53.94M 46.97M
Total operating expenses 57.79M 52.20M 44.38M 52.59M 51.96M
Cost of revenue 7.98M 7.03M 6.94M 6.63M 4.68M
Total other income expense net -6.44M -3.73M -4.91M -4.95M -1.83M
Net income from continuing ops -18.11M -4.37M -5.34M -10.44M -16.38M
Net income applicable to common shares - -4.37M -5.34M -10.44M 21.95M
Preferred stock and other adjustments - - - - -38.33M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 153.52M 42.60M 58.52M 50.85M 50.31M
Intangible assets 97.36M 8.96M 10.90M 12.84M 14.78M
Other current assets 3.91M 2.89M 3.81M 3.72M 2.56M
Total liab 107.35M 63.45M 61.12M 58.83M 54.75M
Total stockholder equity 46.17M -20.85M -2.60M -7.98M -4.45M
Other current liab 12.83M 4.00M 3.40M 3.20M 4.72M
Common stock 0.52M 0.07M 0.07M 0.06M 0.05M
Capital stock 0.52M 19.30M 19.30M 19.28M 30.39M
Retained earnings -418.49M -415.39M -397.28M -392.91M -387.57M
Other liab - - 2.72M 3.56M 3.12M
Good will - - - 12.84M 14.78M
Other assets - - 0.97M 1.47M 0.73M
Cash 12.09M 5.27M 16.51M 11.21M 9.43M
Total current liabilities 21.91M 39.73M 12.59M 12.35M 12.05M
Net debt 55.31M 39.05M 27.06M 33.40M 29.58M
Short term debt 0.83M 25.65M 0.49M 1.69M 0.26M
Short long term debt - 25.31M - 1.48M -
Short long term debt total 67.40M 44.33M 43.57M 44.61M 39.01M
Other stockholder equity 458.57M 378.24M 377.23M 366.20M 353.82M
Property plant equipment - - 4.49M 1.64M 2.05M
Total current assets 52.42M 29.41M 42.16M 34.91M 32.74M
Net tangible assets - - -29.11M -39.53M -49.48M
Net receivables 34.55M 19.61M 19.13M 17.20M 19.33M
Long term debt 64.49M 18.68M 43.08M 42.41M 38.66M
Inventory 1.88M 1.60M 2.68M 2.75M 1.39M
Accounts payable 8.25M 10.09M 8.71M 7.46M 7.08M
Accumulated other comprehensive income 1.69M -3.00M -1.85M -0.55M -1.09M
Common stock total equity - - - 0.06M 0.05M
Preferred stock total equity - - - 19.23M 30.34M
Retained earnings total equity - - - -392.91M -387.57M
Non currrent assets other 0.05M 0.18M 0.83M 0.72M 2.05M
Non current assets total 101.10M 13.19M 16.36M 15.95M 17.56M
Capital lease obligations 0.83M 1.10M 0.49M 0.72M 0.82M
Long term debt total - - - 42.41M 38.66M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.26M -0.62M -0.62M -0.17M -0.17M
Change to liabilities - 1.49M -2.08M 1.81M 2.55M
Total cashflows from investing activities - -0.62M -0.62M -0.17M -0.17M
Net borrowings - -0.22M 3.83M 0.27M 0.99M
Total cash from financing activities -0.30M 9.82M 3.88M 0.87M 0.95M
Change to operating activities - -0.61M -2.87M 0.20M 2.12M
Net income -18.11M -4.37M -5.34M -10.44M -16.38M
Change in cash -11.24M 5.30M 1.78M -3.62M -11.03M
Begin period cash flow 16.54M 11.24M 9.46M 13.07M 24.10M
End period cash flow 5.30M 16.54M 11.24M 9.46M 13.07M
Total cash from operating activities -9.97M -3.22M -2.19M -4.15M -11.55M
Issuance of capital stock 0.09M 10.08M 0.05M 0.90M 0.08M
Depreciation 2.71M 2.58M 2.68M 2.64M 2.65M
Dividends paid - - - - 40.12M
Change to inventory 1.01M -0.02M -1.26M 1.00M -0.93M
Change to account receivables -0.86M -2.21M 2.63M -2.16M -6.00M
Sale purchase of stock - - 0.05M 0.90M -0.12M
Other cashflows from financing activities -0.10M -0.04M 4.28M 40.27M 76.44M
Change to netincome - -1.05M 0.89M 2.99M 5.59M
Capital expenditures 0.26M 0.62M 0.62M 0.17M 0.17M
Change receivables - - 2.63M -2.16M -6.00M
Cash flows other operating - - -0.68M -0.83M 0.13M
Cash and cash equivalents changes - - 1.07M -3.46M -10.78M
Change in working capital 2.69M -1.35M -1.39M -0.18M -4.25M
Stock based compensation 0.91M 1.00M 1.33M 2.46M 4.41M
Other non cash items 1.71M -1.69M 0.50M 0.92M 2.67M
Free cash flow -10.23M -3.85M -2.81M -4.33M -11.73M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MKKGY
Merck KGaA ADR		 -0.22
0.66%		 33.17 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -2.76
1.62%		 167.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.17
0.80%		 21.02 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.85 - 10.66 0.01 1.16 2.94 23.11

Profile*

Alimera Sciences Inc

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

6310 Town Square, Alpharetta, GA, United States, 30005

678 990 5740

https://alimerasciences.com

154

Name Title Year Born
Mr. Charles Daniel Myers Non-Exec. Chairman & Consultant 1954
Mr. Richard S. Eiswirth Jr. Pres, CEO, Interim CFO & Director 1968
Mr. David R. Holland Co-Founder, Chief Marketing Officer and Sr. VP of Corp. Communications & Managed Markets 1964
Dr. Philip Ashman Ph.D. COO & Sr. VP of Commercial Operations - Europe 1965
Christopher S. Visick VP, Gen. Counsel & Sec. NA
Dr. David Dyer M.D. Chief Retina Specialist NA
Mr. Richard S. Eiswirth Jr. CEO & Director 1968
Mr. David R. Holland Co-Founder, Chief Marketing Officer and Senior VP of Corporate Communications & Managed Markets 1964
Dr. Philip Ashman Ph.D. President of International Operations 1965
Mr. Todd Michael Wood President of U.S. Operations 1970

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…